The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System Compared to Standard Management of Type 1 Diabetes in a Singapore Setting

被引:0
|
作者
Gardner, Daphne [1 ]
Lakkad, Mrinmayee [2 ]
Qiu, Zhiyu [3 ]
Inoue, Yuta [2 ]
Chandran, Suresh Rama [1 ]
Wherry, Kael [2 ]
机构
[1] Singapore Gen Hosp, Dept Endocrinol, Singapore, Singapore
[2] Medtron Diabet, Northridge, CA USA
[3] Medtron Singapore, Singapore, Singapore
关键词
Advanced hybrid closed-loop system; Cost-effectiveness; Cost of days off work; Type; 1; diabetes; Singapore; DAILY INSULIN INJECTIONS; QUALITY-OF-LIFE; GLYCEMIC CONTROL; PUMP THERAPY; ADULTS; HYPOGLYCEMIA; REIMBURSEMENT; MULTICENTER; VALIDATION; PREVENTION;
D O I
10.1089/dia.2023.0455
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Despite advances in technology, glycemic outcomes in people with type 1 diabetes (T1D) remain suboptimal. The MiniMed 780G (MM780G) advanced hybrid closed-loop (AHCL) system is the latest technology for T1D management with established safety and efficacy. This study explores the cost-effectiveness of MM780G AHCL compared against multiple daily injections (MDI) plus intermittently scanned continuous glucose monitor (isCGM).Methods: A cost-utility analysis was conducted, simulating lifetime outcomes for 1000 T1D individuals, with baseline hemoglobin A1c of 8.4%, using the IQVIA Core Diabetes Model (CDM) v9.5. A Singapore health care payer perspective was taken with 2023 costs applied. Treatment effects were taken from the ADAPT study and treatment-related events from a combination of sources. T1D complication costs were derived from local literature, and health state utilities and disutilities from published literature. Scenario analyses and probabilistic sensitivity analyses (PSAs) explored uncertainty. Cost-effectiveness was assessed based on willingness-to-pay (WTP) thresholds set to Singapore Dollars (SGD) 45,000 (United States Dollars [USD] 33,087) per quality-adjusted life year (QALY) and Singapore's gross domestic product (GDP) per capita of SGD 114,165 (USD 83,941) per QALY.Results: A switch from MDI plus isCGM to MM780G resulted in expected gains in life-years (+0.78) and QALYs (+1.45). Cost savings through reduction in T1D complications (SGD 25,465; USD 18,723) partially offset the higher treatment costs in the AHCL arm (+SGD 74,538; +USD 54,805), resulting in an estimated incremental cost-effectiveness ratio of SGD 33,797 (USD 24,850) per QALY gained. Findings were robust, with PSA outputs indicating 81% and 99% probabilities of cost-effectiveness at the stated WTP thresholds.Conclusion: MM780G is a cost-effective option for people with T1D managed in a Singapore setting.
引用
收藏
页码:324 / 334
页数:11
相关论文
共 50 条
  • [1] The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden
    Johan Jendle
    M. I. Buompensiere
    A. L. Holm
    S. de Portu
    S. J. P. Malkin
    O. Cohen
    Diabetes Therapy, 2021, 12 : 2977 - 2991
  • [2] Cost-Effectiveness Analysis of an Advanced Hybrid Closed-Loop Insulin Delivery System in People with Type 1 Diabetes in Greece
    Lambadiari, Vaia
    Saltik, Asli Zeynep Ozdemir
    de Portu, Simona
    Buompensiere, Maria Ida
    Kountouri, Aikaterini
    Korakas, Emmanouil
    Sharland, Helen
    Cohen, Ohad
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 (05) : 316 - 323
  • [3] The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden
    Jendle, Johan
    Buompensiere, M. I.
    Holm, A. L.
    de Portu, S.
    Malkin, S. J. P.
    Cohen, O.
    DIABETES THERAPY, 2021, 12 (11) : 2977 - 2991
  • [4] Cost-effectiveness of a novel hybrid closed-loop system compared with continuous subcutaneous insulin infusion in people with type 1 diabetes in the UK
    Roze, Stephane
    Buompensiere, Maria Ida
    Ozdemir, Zeynep
    de Portu, Simona
    Cohen, Ohad
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 883 - 890
  • [5] Cost-effectiveness of advanced hybrid closed loop therapy compared to standard insulin therapy for type 1 diabetes in pregnancy: an economic evaluation of the CRISTAL trial
    Azahaf, Salima
    Beunen, Kaat
    Van Wilder, Nancy
    Ballaux, Dominique
    Vanhaverbeke, Gerd
    Taes, Youri
    Aers, Xavier-Philippe
    Nobels, Frank
    Van Huffel, Liesbeth
    Marlier, Joke
    Lee, Dahae
    Cuypers, Joke
    Preumont, Vanessa
    Siegelaar, Sarah E.
    Painter, Rebecca C.
    Laenen, Annouschka
    Gillard, Pieter
    Mathieu, Chantal
    Luyten, Jeroen
    Benhalima, Katrien
    ECLINICALMEDICINE, 2025, 81
  • [6] PANCREATIC DIABETES EFFECTIVENESS OF AN ADVANCED HYBRID CLOSED-LOOP SYSTEM
    Fernandez-Bueso, M. M.
    Ambrojo Lopez, A.
    Guijarro-Chacon, M. M.
    Nicolas-Blanco, M.
    Beato-Vibora, P. I.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A114 - A115
  • [7] A Response to: Letter to the Editor with Regard to the Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: A Health Economic Analysis in Sweden
    Jendle, J.
    Buompensiere, M. I.
    Holm, A. L.
    de Portu, S.
    Malkin, S. J. P.
    Cohen, O.
    DIABETES THERAPY, 2022, 13 (05) : 1125 - 1129
  • [8] A Response to: Letter to the Editor with Regard to the Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: A Health Economic Analysis in Sweden
    J. Jendle
    M. I. Buompensiere
    A. L. Holm
    S. de Portu
    S. J. P. Malkin
    O. Cohen
    Diabetes Therapy, 2022, 13 : 1125 - 1129
  • [9] ADVANCED HYBRID CLOSED LOOP SYSTEM IN TYPE 1 DIABETES, EXPERIENCE FROM SINGAPORE
    Tian, K.
    Chandran, S. Rama
    Gardner, D. S.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A190 - A190
  • [10] Six-Month Effectiveness of Advanced vs. Standard Hybrid Closed-Loop System in Children and Adolescents With Type 1 Diabetes Mellitus
    Tornese, Gianluca
    Buzzurro, Francesca
    Carletti, Claudia
    Faleschini, Elena
    Barbi, Egidio
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12